Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Descartes-25 in Relapsed/Refractory Multiple Myeloma [Phase 1]
Descartes-25, a candidate from Cartesian Therapeutics, in relapsed/refractory multiple myeloma has a terminated Phase 1 study; no efficacy r…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
This clinical trial update describes switching patients who are intolerant to bortezomib and newly diagnosed with multiple myeloma to carfil…
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression [Phase 2]
Phase 2 trial evaluating low-dose lenalidomide with dexamethasone in relapsed/refractory multiple myeloma patients at high risk for myelosup…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1]
A Phase 1 clinical trial evaluating OL-101 injection in relapsed or refractory multiple myeloma is currently recruiting. The study is sponso…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating romidepsin with lenalidomide in adults with relapsed or refractory lymphomas and multiple myeloma has completed w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients [Phase 3]
Phase 3 trial comparing three lenalidomide-based regimens in elderly multiple myeloma patients; lenalidomide+dexamethasone vs melphalan-pred…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: MInimal Residual Disease Adapted Strategy [Phase 3]
This is a Phase 3 clinical trial update for a Minimal Residual Disease adapted strategy in Multiple Myeloma, sponsored by Intergroupe Franco…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects [Phase 3]
Phase 3 trial in newly diagnosed multiple myeloma comparing cyclophosphamide, lenalidomide, and dexamethasone induction with autologous stem…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies [Phase 1]
Pfizer's Maplirpacept (PF-07901801) Phase 1 trial in hematologic malignancies (lymphoma and multiple myeloma) has completed enrollment/statu…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: MargheRITA (Remote Intelligence for Therapeutic Adherence) [NA]
A completed clinical trial named MargheRITA (Remote Intelligence for Therapeutic Adherence) sponsored by Advice Pharma Group srl studied tre…
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma [Phase 1]
A Phase 1 study evaluating the safety and potential activity of venetoclax in combination with ixazomib citrate and dexamethasone in relapse…
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients
A clinical trial from Assiut University is investigating the significance of specific hyperdiploidy patterns (5p15, 9q22, 15q22) in patients…
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of ION251 in patients with relapsed or refractory multiple myeloma has completed.
-
FDA approval · 2024-10-29FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Nexus Pharmaceuticals, LLC)
FDA approved Nexus Pharmaceuticals, LLC to market a generic cyclophosphamide product under Original Application ANDA216783.
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer conducted a study to evaluate the effectiveness of Elranatamab in relapsed or refractory multiple myeloma; the trial has completed an…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
This document reports a real-world observational study evaluating Zevorcabtagene Autoleucel for relapsed/refractory multiple myeloma, with t…
-
CLINICAL_TRIALS trial_result · 2024-10-26Clinical Trial Update: Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma [NA]
A clinical trial evaluating cryocompression therapy for chemotherapy-induced peripheral neuropathy in patients with multiple myeloma was ter…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
A clinical trial evaluating whole body diffusion-weighted MRI (DWI) versus FDG PET/CT in symptomatic multiple myeloma; the study is currentl…
-
CLINICAL_TRIALS trial_result · 2024-10-26Clinical Trial Update: Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of novel regimens for relapsed or refractory multiple myeloma has been terminated.
-
FDA approval · 2024-10-25FDA Approved: SARCLISA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for SARCLISA (isatuximab) from Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]
Phase 3 trial evaluating efficacy and safety of belantamab mafodotin in combination with bortezomib and dexamethasone versus daratumumab wit…
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia [Phase 1]
Phase 1 exploratory study of RD140 injection in patients with relapsed/refractory multiple myeloma or plasma cell leukemia; the trial is not…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03) [Phase 1]
Phase 1 trial evaluating total marrow irradiation with high-dose melphalan as conditioning for autologous stem cell transplantation in relap…
-
EMA approval · 2024-10-18EMA Authorised: Velcade (bortezomib) — Janssen-Cilag International NV
The EMA authorised Velcade (bortezomib) from Janssen-Cilag International NV for use in multiple myeloma.
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: LMY-920 for Treatment of Relapsed or Refractory Myeloma [Phase 1]
Phase 1 clinical trial update for LMY-920 in relapsed or refractory multiple myeloma; recruitment is ongoing by Luminary Therapeutics.